<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89567AAF-2DC2-44FC-9DC1-58C569EB26D2"><gtr:id>89567AAF-2DC2-44FC-9DC1-58C569EB26D2</gtr:id><gtr:name>Iron Horse Diagnostics, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/04235AE0-B417-4637-A969-0769E3F91954"><gtr:id>04235AE0-B417-4637-A969-0769E3F91954</gtr:id><gtr:name>EU Joint Programme - Neurodegenerative Disease Research (JPND)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BAF7118-A7CB-4385-903E-255DD6F6908A"><gtr:id>7BAF7118-A7CB-4385-903E-255DD6F6908A</gtr:id><gtr:name>Friedrich Schiller University Jena (FSU)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89567AAF-2DC2-44FC-9DC1-58C569EB26D2"><gtr:id>89567AAF-2DC2-44FC-9DC1-58C569EB26D2</gtr:id><gtr:name>Iron Horse Diagnostics, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/04235AE0-B417-4637-A969-0769E3F91954"><gtr:id>04235AE0-B417-4637-A969-0769E3F91954</gtr:id><gtr:name>EU Joint Programme - Neurodegenerative Disease Research (JPND)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BAF7118-A7CB-4385-903E-255DD6F6908A"><gtr:id>7BAF7118-A7CB-4385-903E-255DD6F6908A</gtr:id><gtr:name>Friedrich Schiller University Jena (FSU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CF74FEB1-A15E-4984-A768-008B70F12C51"><gtr:id>CF74FEB1-A15E-4984-A768-008B70F12C51</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Turner</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK000780%2F1"><gtr:id>6CEFDC9E-9C29-473C-8F60-1117CCB74B9C</gtr:id><gtr:title>Sampling, biomarker OPtimization and Harmonization In ALS (SOPHIA)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K000780/1</gtr:grantReference><gtr:abstractText>Amyotrophic Lateral Sclerosis (ALS) is one of the most devastating diseases in neurology affecting some 50,000 individuals at any time in Europe, and causing around 10,000 deaths each year. The main clinical features are weakness and wasting of muscles, but dementia may also occur. ALS represents a good model for study of all neurodegenerative conditions, as it has a characteristic phenotype, rapid progression and the correlation between diagnosis during life and autopsy diagnosis is close to 100%. However, validated neurochemical biomarkers for monitoring disease activity, for generating earlier diagnoses and for defining prognosis are lacking. Active European collaborations are in place for harmonizing clinical datasets, neuroimaging and neuropathology protocols. A preliminary strategy for harmonization of biological and tissue samples has been established. Standardized protocols for clinical data and sample collection are now urgently required for optimization and harmonization of biomarker development. 
The overall aim of this proposal is to provide a common European strategy for the prioritization and selection of candidate biomarker domains for optimization and harmonization. This will in turn provide a long-term platform by which existing collaborative structures that are relevant to neurodegenerative disease biomarkers (including academic initiatives, co-funding strategies, biobanks, industrial efforts, private-public alliances) are integrated within an inclusive web-based virtual biobank. Samples and clinical/imaging/neurophysiologic and neuropathological datasets provided by participating members can then be optimally utilized to enable state of the art collaborative analyses.
The established platform will also act as an important communication channel between this consortium and the rest of the ALS/Neurodegeneration field to ensure that the optimization efforts are in line with the whole ALS/ND field, to avoid duplication of work, and to ensure better acceptance and utilization of the project results by all stakeholders. Ultimately, the platform will be used to disseminate the results to the whole ALS/Neurodegeneration field, and will act as a permanent Interactive European ALS biomarker platform for researchers to optimize/harmonize novel biomarkers using an established pan-European ALS methodology. The platform will also allow interaction with those of other cognate groups (e.g the NEALS group within the US) and with patient groups and other relevant stakeholders.</gtr:abstractText><gtr:technicalSummary>Tasks in the MRI component of SOPHIA:
T1. Registration of participating EU ALS centres to the Jena MRI database.
T2. Establish bidirectional interface to the core clinical data management.
T3. Assessment of acquisition parameters driving variability in T1W and DTI datasets 
T4. Comparison of group-level results from different analysis platforms (SPM versus FSL versus TIFT).
T5. Identification of a standardised protocol for T1W and DTI acquisition.
T6. Linkage of core dataset and non-MRI biomarkers to individual MRI datasets to explore the additional value of a multimodal profile.
T7. Implementation of standardised protocol prospectively in ALS and healthy control subjects.
T8. Publication and international challenge of neurodegenerative disease research groups to test protocol against non-ALS neurodegenerative disease cases.
T9. Re-assessment of variability of both pre-processed MRIs and results post-analysis in prospective data, through multi-site data sharing (inter and intra-site variability).
T10. Correlation with post-mortem neuropathology reports in a subset of centers adhering to the standards of established European brain banks.
T11. Application of quality control systems to other MRI modalities i.e. resting state fMRI, MR spectroscopy and advanced fibre track analysis tools of DTI.
T12. Implementation of a continuous quality control framework which feeds back to participating centres.</gtr:technicalSummary><gtr:potentialImpactText>This project has benefit for patients with MND and their carers, through the development of much-needed biomarkers of disease progression and phenotype. These can improve care planning and the development of therapeutic agents for a devastating neurological disorder.

The project will deliver standardization and harmonization of candidate biomarkers across multiple EU MND centres so that there is a coherent approach to this vital area of need, avoiding duplication of work and wasted resources. The inherent QC aspect means that valuable biofluid samples and MRI scans are acquired and stored consistently to allow meaningful comparison of results across centres.

The project establishes a platform that will be accessible to global research communities involved in neurodegenerative biomarker development, many of whom use similar biofluid and advanced MRI technology within other diseases. Information about variability of measures across sites, and issues of QC have great potential to save time and resources.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>73101</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Friedrich Schiller University Jena (FSU)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>NISALS</gtr:description><gtr:id>AC7239B6-159C-49AB-B086-81EE9FCDB4ED</gtr:id><gtr:impact>Consensus statementas on neuroimaging in ALS (Lancet Neurology 2011 and 2015).
Multi-site analysis of T1 and DTI data (paper on DTI 2016).
Paper on clinical correlations 2016</gtr:impact><gtr:outcomeId>QMPgxTnZyAg-1</gtr:outcomeId><gtr:partnerContribution>Online repository for multi-site MRI data for multi-site analyses.</gtr:partnerContribution><gtr:piContribution>Establishment of an international consortium of neuroscientists focused on neuroimaging in ALS.
Organise annual meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Iron Horse Diagnostics, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Neurofilaments</gtr:description><gtr:id>8575591D-4CA0-4FB0-B7CC-FE912FA88DD7</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-2</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EU Joint Programme - Neurodegenerative Disease Research (JPND)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>SOPHIA</gtr:description><gtr:id>5B9F09B7-C077-4A89-889E-2A3214A8B808</gtr:id><gtr:impact>Initial analysis of multisite variability in MRI (T1 and DTI). DTI paper 2016.
Initial multisite comparison of neurochemical markers in CSF and serum. Round robin papers 2014 and 2016.
Initial multisite comparison of MUNIX neuropysiology data.</gtr:impact><gtr:outcomeId>CpY1jHzcwd8-1</gtr:outcomeId><gtr:partnerContribution>Other centres have contributed MRI and neurochemical data for cross-site comparison studies.</gtr:partnerContribution><gtr:piContribution>This consortium of ~20 EEA countries responded to a call from the JPND to address standardization and optimization of biomarker candidates in ALS.
I wrote the MRI-based part of this bid, and am coordinating the implementation.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Research Facilities</gtr:department><gtr:description>Neurofilaments</gtr:description><gtr:id>DFCA0B9C-E826-40C9-9DD0-8489B88104A1</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-1</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ulm</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Neurofilaments</gtr:description><gtr:id>037F2D24-5506-40EE-9471-4EF57C7C53E7</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-3</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Biogen Idec Imaging Advisory Panel</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>53CEB158-3609-434E-BF78-14CED3AB1614</gtr:id><gtr:impact>Expert view on use of neuroimaging for ALS biomarkers

Company keen to pursue</gtr:impact><gtr:outcomeId>5463a8f57f10b1.12114284</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CSF Society</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2E0AFD0A-93EE-45EF-B971-F6C6C10683B0</gtr:id><gtr:impact>Collaboration and standardisation on all aspects of CSF analysis</gtr:impact><gtr:outcomeId>58bc427c8282c6.09083076</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Taubman Institute Lectureship</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FF9978FD-8772-46DC-9131-3107C38B094C</gtr:id><gtr:impact>Invited presentation on ALS biomarkers

Stimulate local research and advice on logistics.</gtr:impact><gtr:outcomeId>5463a79d21f1c6.80177765</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ALSRG</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E47EF1D5-4606-4438-9AB0-30F089ED57A9</gtr:id><gtr:impact>Discussions around clinical trials and funding for ALS research

Planned meeting to redesign clinical trials in ALS</gtr:impact><gtr:outcomeId>5463a95608b476.09432747</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOPHIA meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>09754DE9-4D63-48F5-B8CF-6216049459F4</gtr:id><gtr:impact>Joint meeting to discuss progress and strategy in SOPHIA project.

Advancement of project goals and wider multi-site collaborative work.</gtr:impact><gtr:outcomeId>GnWxBMgBjGg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.sophiaproject.eu</gtr:url><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brazilian ALS Outreach</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8A9F5CCF-1364-438B-9E28-5EA3F59D6F4D</gtr:id><gtr:impact>Invited presentations to ALS neurologists and researchers in Brazil (Sao Paulo and Curitiba)

New collaborations planned, and advice on setting up infrastructure for ALS care and research in Brazil.</gtr:impact><gtr:outcomeId>5463accd067641.33108410</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICCN meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3294DEEC-686D-40A4-AD0C-B2432927BB5F</gtr:id><gtr:impact>Invited presentation on neuroimaging biomarkers in ALS

Increased awareness and profile-raising</gtr:impact><gtr:outcomeId>5463a711ec9804.36749811</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100100</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Thierry Latran Foundation 4th Project Call</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Thierry Latran Foundation</gtr:fundingOrg><gtr:fundingRef>PROMISES</gtr:fundingRef><gtr:id>DBCAE8B9-1FBD-42FC-A310-F0B9CEF5E1B7</gtr:id><gtr:outcomeId>JHEPLs1LFHz</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>The Neuroimaging Symposium in Amyotrophic lateral sclerosis (ALS) (NISALS)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9A993FED-4E74-4019-B60C-7542EA0D55E5</gtr:id><gtr:impact>I convened the first meeting in 2010, now annual, of global researchers studying ALS using neuroimaging. Guidelines were developed and published in Lancet Neurology PMID:21511189. Second meeting in Jena Germany 2011 has laid foundation for standardization and harmonization of MRI data across centres. Meeting in Miami developing multi-centre collaborative MRI study. Meetings in Milan, Leuven, Orlando and Dublin have developed multi-centre projects and Governance framework.</gtr:impact><gtr:outcomeId>PTWjRE1fi33</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21511189</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Roadmap for 'wet' biomarker development in Amyotrophic lateral sclerosis (ALS)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2D9A1CD4-1F38-45D5-AB86-7F538823D5D3</gtr:id><gtr:impact>Produced international consensus statement (with me as co-first author) on future development and validation of 'wet' biomarkers in ALS, Published in ALS journal.</gtr:impact><gtr:outcomeId>BZNfVNDn92W</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ENMC Workshop on EU Consensus in Amyotrophic lateral sclerosis (ALS)</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>F4314C2B-AF8C-4EC2-9221-44233E592215</gtr:id><gtr:impact>Led to formation of ENCALS - The European Network for the Cure of ALS which has led on to numerous research grants, meetings, and clinical trials.</gtr:impact><gtr:outcomeId>PiBbdP4VUhq</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.encals.eu</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>CSF NFL as a diagnostic, predictive and pharmacodynamic biomarker in ALS</gtr:description><gtr:id>49B47014-C31D-4850-943E-F0215DE9F842</gtr:id><gtr:impact>International workshop planned for harmonisation of efforts.</gtr:impact><gtr:outcomeId>56d2ed9580e451.19378052</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>NFL</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Ethical approval to seek consent for extra sample of CSF and blood from patients having routine investigations, to use as disease controls in biomarker studies.</gtr:description><gtr:id>53644832-56F9-4022-B662-277012FE503F</gtr:id><gtr:impact>Access to disease controls for ALS biomarker development, including contribution to standardisation efforts.
New collaborations with local groups increases sample collecting infrastructure.</gtr:impact><gtr:outcomeId>5463b7ae9492b4.66224218</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Oxford Biomarker Bank</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Repository for multi-centre MRI data in MND.</gtr:description><gtr:id>C1622B7B-8037-40A6-8DEE-7D0A19F22588</gtr:id><gtr:impact>Quality control process for T1-weighted MRIs for VBM analysis.
Platform for future multi-centre meta-analyses.</gtr:impact><gtr:outcomeId>bcdjpuvuibN</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Jena MRI repository</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://www.nisals.org</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>207049E2-269E-46A9-9EE6-668F69450FF1</gtr:id><gtr:title>Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54637a5768bb70.81114586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E33C0200-B773-435F-931F-DCFB54AD4CD8</gtr:id><gtr:title>Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2deb3bad43536c8c939526c0265dbb29"><gtr:id>2deb3bad43536c8c939526c0265dbb29</gtr:id><gtr:otherNames>Filippi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56d2c61b5f1623.80484490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BD4EA62-EA7B-4E6D-B366-4C4BDD408604</gtr:id><gtr:title>Mind the gap: the mismatch between clinical and imaging metrics in ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d791b9fa6835f750f5e1c9494b2bad8"><gtr:id>9d791b9fa6835f750f5e1c9494b2bad8</gtr:id><gtr:otherNames>Verstraete E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d2c61d7e0c46.90452459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B26481F3-6BC8-4A17-80AA-69DA82D8FAE3</gtr:id><gtr:title>Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis.</gtr:title><gtr:parentPublicationTitle>Academic radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12694b6fc260157c5202509072982484"><gtr:id>12694b6fc260157c5202509072982484</gtr:id><gtr:otherNames>Foerster BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1076-6332</gtr:issn><gtr:outcomeId>pm_12643_23_23931423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EEDAC38-636D-483C-90F5-1FB7686291D0</gtr:id><gtr:title>A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcdc79518e85ab24b449aa0dc5ef6366"><gtr:id>dcdc79518e85ab24b449aa0dc5ef6366</gtr:id><gtr:otherNames>M?ller HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61aa46d38.87946622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F98E7FB-E88D-4B39-83A8-F7C488D786F3</gtr:id><gtr:title>Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fa71eb5bcb5dbba5a77cb5d30c89ec3"><gtr:id>9fa71eb5bcb5dbba5a77cb5d30c89ec3</gtr:id><gtr:otherNames>Oeckl P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>585d6ff0ba4d60.28154543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32D8E3AE-939C-4849-97B2-396AE7DEEAA5</gtr:id><gtr:title>Spread of pedigree versus genetic ancestry in spatially distributed populations.</gtr:title><gtr:parentPublicationTitle>Theoretical population biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c63964e4077a3d288c00e625613d207"><gtr:id>9c63964e4077a3d288c00e625613d207</gtr:id><gtr:otherNames>Kelleher J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-5809</gtr:issn><gtr:outcomeId>56cc3a809f2735.76436086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72175E0F-B083-459E-8C21-DE1DE609D4DB</gtr:id><gtr:title>Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?</gtr:title><gtr:parentPublicationTitle>Alzheimer's research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ea7cb7c5b66d2c17f42873f65f06866"><gtr:id>1ea7cb7c5b66d2c17f42873f65f06866</gtr:id><gtr:otherNames>Merlo Pich E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d2c61e39c0e6.29393236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48B9FD6E-08B6-401E-9C65-281BC8AEC143</gtr:id><gtr:title>Quantifying disease progression in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1039732cd08f0b19b673004518ad2ad4"><gtr:id>1039732cd08f0b19b673004518ad2ad4</gtr:id><gtr:otherNames>Simon NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>54637a57b7d835.14138573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02A81650-8C52-48C8-87EB-97A9846AEAC9</gtr:id><gtr:title>Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>54637a57e4a135.06339835</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000780/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>